title: Male breast cancer: management and follow-up recommendations.
abstract: National Comprehensive Cancer Network (NCCN) guidelines for female breast cancer treatment and surveillance are well established, but similar guidelines on male breast cancers are less recognized. As an NCCN institution, our objective was to examine practice patterns and follow-up for male breast cancer compared to established guidelines for female patients. After Institutional Review Board approval, a prospective breast database from 1990 to 2009 was queried for male patients. Medical records were examined for clinico-pathological factors and follow-up. The 5-year survival rates with 95% confidence intervals were estimated using Kaplan-Meier method and Greenwood formula. Of the 19,084 patients in the database, 73 (0.4%) were male patients; 62 had complete data. One patient had bilateral synchronous breast cancer. The median age was 68.8 years (range 29-85 years). The mean/median invasive tumor size was 2.2/1.6 cm (range 0.0-10.0 cm). All cases had mastectomy (29 with axillary node dissection, 23 with sentinel lymph node biopsy only, 11 with sentinel node biopsy followed by completion axillary dissection). Lymph node involvement occurred in 25/63 (39.7%). Based on NCCN guidelines, chemotherapy, hormonal therapy, and radiation are indicated in 34 cases, 62 cases, and 14 cases, respectively. Only 20/34 (59%) received chemotherapy, 51/62 (82%) received hormonal therapy, and 10/14 (71%) received post-mastectomy radiation. Median follow-up was 26.2 months (range: 1.6-230.9 months). The 5-year survival estimates for node positive and negative diseases were 68.5% and 87.5%, respectively (p = 0.3). Despite the rarity of male breast cancer, treatment options based on current female breast tumors produce comparable results to female breast cancer. Increased awareness and a national registry for patients could help improve outcomes and tailor treatment recommendations to the male variant.
authors: Comprehensive Breast Program, Department of Women's Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida 33612, USA. john.kiluk@moffitt.org
authors: John V
authors: JV
authors: Kiluk
authors: Marie Catherine
authors: MC
authors: Lee
authors: Catherine K
authors: CK
authors: Park
authors: Tammi
authors: T
authors: Meade
authors: Susan
authors: S
authors: Minton
authors: Eleanor
authors: E
authors: Harris
authors: Jongphil
authors: J
authors: Kim
authors: Christine
authors: C
authors: Laronga
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology* / Q000628:therapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001365:Axilla; D018567:Breast Neoplasms, Male / Q000473:pathology* / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D019983:Guideline Adherence; D006801:Humans; D053208:Kaplan-Meier Estimate; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008297:Male; D008408:Mastectomy; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D018714:Radiotherapy, Adjuvant; D021701:Sentinel Lymph Node Biopsy